A Pan-Antiviral, Antibacterial, Antifungal, and Antiprotozoal Therapy
Background
Globally, intracellular pathogens—including viruses, bacteria, fungi, and protozoa—affect hundreds of millions of people and cause millions of deaths each year. Bacterial infections account for approximately 7.7 million deaths (one in eight worldwide) and affect over one billion people. Fungal infections cause an estimated 3.8 million deaths, while viral infections lead to about 8.7 million deaths annually.
Existing therapies are highly pathogen-specific, limiting their usefulness. Moreover, current treatments exert direct selective pressure on pathogens, driving mutation and the emergence of drug-resistant strains.
Our Approach
BG-401 is a host-directed, orally administered small molecule that inhibits a pathway in host cells that multiple pathogens need for infection, survival, or replication.
By targeting a host mechanism common to diverse pathogens, BG-401 functions as a pan-anti-pathogen therapy across multiple pathgenn domains.
Because selective pressure is not directed at the pathogens themselves, and the initial co-optation opportunities are reduced, the risk of resistance development is expected to be minimal.
BG-401 is being developed for influenza, herpes simplex (HSV), and drug-resistant chlamydia, with potential additional indications.
Potential ImpactBG-401 targets the $10 billion-plus global antimicrobial market, aiming to reduce transmission, illness, and mortality.
BG-401 can potentially serve as a first-response therapeutic for a broad spectrum of pathogens. Its oral formulation enables rapid deployment in early outbreaks and routine clinical use. Because BG-401 is not pathogen-specific, it could also act as an immediate countermeasure against emerging or previously unknown infections, addressing a critical need in global pandemic preparedness.
StatusPreclinical.
biOOrg3.14 is actively seeking investment and strategic partnerships to accelerate clinical development of BG-401.